4-oxo-4,5-dihydrothieno[2,3-c]quinoline-8-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-oxo-4,5-dihydrothieno[2,3-c]quinoline-8-carbonitrile
• 英文别名: 4-oxo-5H-thieno[2,3-c]quinoline-8-carbonitrile
• 化学式: C₁₂H₆N₂OS
• 分子量: 226.258
• InChiKey: SNKSXKDXKTXYQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氯噻吩-2-甲酰氯 在 三乙胺 作用下， 以 甲苯 为溶剂， 反应 11.0h， 生成 4-oxo-4,5-dihydrothieno[2,3-c]quinoline-8-carbonitrile
  参考文献：
  名称：

  Exploring antiproliferative activity of heteroaromatic amides and their fused derivatives using 3D-QSAR, synthesis, and biological tests

  摘要：

  In this manuscript the synthesis, antiproliferative activity, and 3D-QSAR study of novel heteroaromatic benzamides and their cyclic products, quinolones and naphthyridones were described. The in vitro antiproliferative screening on three tumor cell lines showed in general moderate antiproliferative effect, except 2-benzimidazolyl and 2-benzothiazolyl substituted heteroaromatic amides, which showed prominent antiproliferative effect with GI(50) concentration at micromolar range. Cyclic quinolones and naphthyridones demonstrated similar activity as their acyclic precursors. Using measured anticancer activities, 3D-QSAR models were obtained. Their prediction abilities were tested by internal and external prediction. Molecular properties with the highest positive or negative influence on compound's anticancer activities have been identified. It was found that possibility of compound to accept H-bond (WN1), sum of hydrophobic surface areas, possibility of weak hydrophobic interactions (D1), and complete molecular surface of compound (S) should be increased, while possibility of weak hydrophilic interactions (W1) should be decreased in order to enhance anticancer activity of investigated compounds.

  DOI：

  10.1007/s00706-015-1478-8

文献信息

• [EN] TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME<br/>[FR] COMPOSÉS TRICYCLIQUES ET INHIBITEURS DE PBK LES CONTENANT
  申请人：ONCOTHERAPY SCIENCE INC

  公开号：WO2011123419A1

  公开（公告）日：2011-10-06

  Trycyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.

  提供的是三环化合物。这些化合物是PBK抑制剂，可用于治疗与PBK相关的疾病，包括癌症。
• TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME
  申请人：Nakamura Yusuke

  公开号：US20130178459A1

  公开（公告）日：2013-07-11

  Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.

  提供三环化合物。这些化合物是PBK抑制剂，可用于治疗与PBK相关的疾病，包括癌症。
• Tricyclic Compounds and PBK Inhibitors Containing the Same
  申请人：ONCOTHERAPY SCIENCE, INC.

  公开号：US20150183799A1

  公开（公告）日：2015-07-02

  Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.

  提供三环化合物。这些化合物是PBK抑制剂，可用于治疗与PBK相关的疾病，包括癌症。
• TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME
  申请人：OncoTherapy Science, Inc.

  公开号：EP2552206A1

  公开（公告）日：2013-02-06
• US8962648B2
  申请人：——

  公开号：US8962648B2

  公开（公告）日：2015-02-24